Oral GPIIb/IIIa antagonists: What went wrong?

Current Pharmaceutical Design

Volumn 10, Issue 14, 2004, Pages 1587-1596

  Cox, Dermot ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETYL]AMINO] N (BUTOXYCARBONYL)ALANINE; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CROMAFIBAN; ELAROFIBAN; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; FRADAFIBAN; HEPARIN; LAMIFIBAN; LEFRADAFIBAN; LOTRAFIBAN; ORBOFIBAN; RO 44 3888; ROXIFIBAN; SC 57101; SC 57401; SIBRAFIBAN; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; UR 3216; XEMILOFIBAN; YM 028;

ADJUVANT THERAPY; ANTICOAGULANT THERAPY; BINDING SITE; BLEEDING; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; GENETIC POLYMORPHISM; HEART MUSCLE ISCHEMIA; HUMAN; MORTALITY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SHORT COURSE THERAPY; SKIN BRUISING; STOMACH ULCER; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT FAILURE;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANIMALS; CLINICAL TRIALS; CORONARY DISEASE; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOSIS;

EID: 2342436814     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384673     Document Type: Review

References (78)

1. Fitzgerald D, Roy L, Catella F, FitzGerald G. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-9.
2. Elwood P, Cochrane A, Burr M, Sweetnam P, Williams G, Welsby E, et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J 1974; 1: 436-40.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
4. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321: 1183-7.
5. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-5.
6. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.
7. Niewiarowski S, McLane M, Kloczewiak M, Stewart G. Disintegrins and other naturally occurring antagonists of platelet fibrinogen receptors. Semin Hematol 1994; 31: 289-300.
8. Newby LK, Califf RM, White HD, Harrington RA, Van de Werf F, Granger CB, et al. The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. Am J Med 2002; 112: 647-58.
9. Hellstrom HR. Platelet Glycoprotein IIb/IIIa Inhibitors. Circulation 2003; 107: 39e-.
10. Nicholson N, Panzer-Knodle S, Haas N, Taite B, Szalony J, Page J, et al. Assessment of platelet function assays. American Heart Journal 1998; 135: S170-8.
11. Cox D, Smith R, Quinn M, Theroux P, Crean P, Fitzgerald DJ. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000; 36: 1514-9.
12. Phillips DR, Teng W, Arfsten A, Nannizzi-Alaimo L, White MM, Longhurst C, et al. Effect of Ca2+ on GP IIb-IIIa Interactions With Integrelin: Enhanced GP IIb-IIIa Binding and Inhibition of Platelet Aggregation by Reductions in the Concentration of Ionized Calcium in Plasma Anticoagulated With Citrate. Circulation 1997; 96: 1488-94.
13. Hezard N, Metz D, Nazeyrollas P, Droulle C, Elaerts J, Potron G, et al. Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of c7E3 Fab in the presence of other antiplatelet agents. Thrombosis and Haemostasis 2000; 83: 540-4.
14. Theroux P, Gosselin G, Nasmith J, Cox D, Fitzgerald D, Burns D, et al. The Accumetrics Rapid Platelet Function Analyzer (RPFA®) to Monitor Platelet Aggregation During Oral Administration of a GPIIb/IIIa Antagonist. Journal Americam College of Cardiology 1999; Abstract.
15. Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists. Circulation 1999; 99: 2231-8.
16. Nicholson NS, Panzer-Knodle SG, Salyers AK, Taite BB, Szalony JA, Haas NF, et al. SC-54684A: an orally active inhibitor of platelet aggregation. Circulation 1995; 91: 403-10.
17. Szalony JA, Haas NF, Salyers AK, Taite BB, Nicholson NS, Mehrotra DV, et al. Extended Inhibition of Platelet Aggregation With the Orally Active Platelet Inhibitor SC-54684A. Circulation 1995; 91: 411-6.
18. Anders R, Kleiman J, Nicholson N, Wazowicz B, Burns D. Xemilofiban/orbofiban: insight into drug development. Cardiovasc Drug Rev 2001; 19: 116-32.
19. Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, et al. First Chronic Platelet Glycoprotein IIb/IIIa Integrin Blockade : A Randomized, Placebo-Controlled Pilot Study of Xemilofiban in Unstable Angina With Percutaneous Coronary Interventions. Circulation 1997; 96: 76-81.
20. Kereiakes DJ, Kleiman N, Ferguson JJ, Runyon JP, Broderick TM, Higby NA, et al. Sustained Platelet Glycoprotein IIb/IIIa Blockade With Oral Xemilofiban in 170 Patients After Coronary Stent Deployment. Circulation 1997; 96: 1117-21.
21. Kereiakes DJ, Kleiman NS, Ferguson JJ, Masud ARZ, Broderick TM, Abbottsmith CW, et al. Pharmacodynamic Efficacy, Clinical Safety, and Outcomes After Prolonged Platelet Glycoprotein IIb/IIIa Receptor Blockade With Oral Xemilofiban: Results of a Multicenter, Placebo-Controlled, Randomized Trial. Circulation 1998; 98: 1268-78.
22. O'Neill WW, Serruys P, Knudtson M, van Es G-A, Timmis GC, van der Zwaan C, et al. The EXCITE Trial Investigators. Long-Term Treatment with a Platelet Glycoprotein-Receptor Antagonist after Percutaneous Coronary Revascularization. N Engl J Med 2000; 342: 1316-24.
23. Nicholson NS, Abood NA, Panzer-Knodle SG, Frederick LG, Page JD, Salyers AK, et al. Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist. Med Res Rev 2001; 21: 211-26.
24. Wang X, Dorsam RT, Lauver A, Wang H, Barbera FA, Gibbs S, et al. Comparative Analysis of Various Platelet Glycoprotein IIb/IIIa Antagonists on Shear-Induced Platelet Activation and Adhesion. J Pharmacol Exp Ther 2002; 303: 1114-20.
25. Ogawa T, Sugidachi A, Naganuma H, Asai F. Antiplatelet and Antithrombotic Effects of Orbofiban, a New Orally Active GPIIb/IIIa Antagonist, in Guinea Pigs. Thrombosis Research 2000; 97: 307-15.
26. Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000; 102: 149-56.
27. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial. J Am Coll Cardiol 1998; 32: 2003-10.
28. Refino CJ, Modi NB, Bullens S, Pater C, Lipari MT, Robarge K, et al. Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form. Thromb Haemost 1998; 79: 169-76.
29. Modi N, Lin Y, Reynolds T, Shaheen A, Christian B. Pharmacokinetics and pharmacodynamics of sibrafiban (Ro 48-3657), an orally active IIb/IIIa antagonist, administered alone or in combination with heparin, aspirin, and recombinant tissue-type plasminogen activator in beagles. J Cardiovasc Pharmacol 1998; 32: 397-405.
30. Wittke B, Mackie IJ, Machin SJ, Timm U, Zell M, Goggin T. Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers. Br J Clin Pharmacol 1999; 47: 521-30.
31. Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, et al. Randomized Trial of an Oral Platelet Glycoprotein IIb/IIIa Antagonist, Sibrafiban, in Patients After an Acute Coronary Syndrome : Results of the TIMI 12 Trial. Circulation 1998; 97: 340-9.
32. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The Lancet 2000; 355: 337-45.
33. Randomized Trial of Aspirin, Sibrafiban, or Both for Secondary Prevention After Acute Coronary Syndromes. Circulation 2001; 103: 1727-33.
34. Wong A, Hwang SM, Johanson K, Samanen J, Bennett D, Landvatter SW, et al. Binding of [3H]-SK&F 107260 and [3H]-SB 214857 to Purified Integrin alpha IIbbeta 3: Evidence for a Common Binding Site for Cyclic Arginyl-Glycinyl-Aspartic Acid Peptides and Nonpeptides. J Pharmacol Exp Ther 1998; 285: 228-35.
35. Toomey J, Samanen J, Valocik R, Koster P, Barone F, Willette R. The antithrombotic efficacy of lotrafiban (SB 214857) in canine models of acute coronary thrombosis. Curr Drug Targets Cardiovasc Haematol Disord 2002; 2: 13-25.
36. Mould D, Chapelsky M, Aluri J, Swagzdis J, Samuels R, Granett J. A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients. Clin Pharmacol Therapeut 2001; 69: 210-22.
37. Harrington RA, Armstrong PW, Graffagnino C, Van de Werf F, Kereiakes DJ, Sigmon KN, et al. Dose-Finding, Safety, and Tolerability Study of an Oral Platelet Glycoprotein IIb/IIIa Inhibitor, Lotrafiban, in Patients With Coronary or Cerebral Atherosclerotic Disease. Circulation 2000; 102: 728-35.
38. Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM, Graffagnino C, et al. Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular Disease. Circulation 2003; 108: 399-406.
39. Muller TH, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J. Profound and Sustained Inhibition of Platelet Aggregation by Fradafiban, a Nonpeptide Platelet Glycoprotein IIb/IIIa Antagonist, and Its Orally Active Prodrug, Lefradafiban, in Men. Circulation 1997; 96: 1130-8.
40. Akkerhuis KM, Neuhaus K-L, Wilcox RG, Vahanian A, Boland J-L, Hoffmann J, et al. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation A phase II study. Eur Heart J 2000; 21: 2042-55.
41. Akkerhuis KM, van den Brand MJBM, van der Zwaan C, Peels HOJ, Suryapranata H, van der Wieken LR, et al. Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. Head 2001; 85: 444-50.
42. Mousa S, Forsythe M, Lorelli W, Bozarth J, Xue C, Wityak J, et al. Novel nonpeptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specificity. Coron Artery Dis 1996; 7: 767-74.
43. Mousa SA, Bozarth JM, Lorelli W, Forsythe MS, Thoolen MJMC, Slee AM, et al. Antiplatelet Efficacy of XV459, A Novel Nonpeptide Platelet GPIIb/IIIa Antagonist: Comparative Platelet Binding Profiles with c7E3. J Pharmacol Exp Ther 1998; 286: 1277-84.
44. Mousa SA, Bozarth JM, Forsythe MS, Slee A. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: Role of plasma calcium levels. Cardiovasc Res 2000; 47: 819-26.
45. Mousa SA, Kapil R, Mu D-X. Intravenous and Oral Antithrombotic Efficacy of the Novel Platelet GPIIb/IIIa Antagonist Roxifiban (DMP754) and Its Free Acid Form, XV459. Arterioscler Thromb Vasc Biol 1999; 19: 2535-41.
46. Pieniaszek HJ, Sy S, Ebling W, Fossler M, Cain V, Mondick J, et al. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers. J Clin Pharmacol 2002; 42: 738-53.
47. Frelinger A, Cohen I, Plow E, Smith M, Roberts J, Lam S, et al. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J Biol Chem 1990; 265: 6346-52.
48. Kouns WC, Kirchhofer D, Hadvary P, Edenhofer A, Weller T, Pfenninger G, et al. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood 1992; 80: 2539-47.
49. Jennings L, Haga J, Slack S. Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists. Thromb Haemost 2000; 84: 1095-102.
50. Honda S, Tomiyama Y, Aoki T, Shiraga M, Kurata Y, Seki J, et al. Association Between Ligand-Induced Conformational Changes of Integrin alpha IIbbeta 3 and alpha IIbbeta 3-Mediated Intracellular Ca2+ Signaling. Blood 1998; 92: 3675-83.
51. Quinn MJ, Fullard J, Kerrigan S, Harriott P, Cox D, Fitzgerald DJ. Characterization of a ligand-attenuated binding site on glycoprotein IIb/IIIa. Thromb Haemost 2002; 88: 811-6.
52. Cox D, Aoki T, Seki J, Motoyama Y, Yoshida K. Pentamidine is a specific, non-peptide, GPIIb/IIIa antagonist. Thromb Haemost 1996; 75: 503-9.
53. Holmes MB, Sobel BE, Cannon CP, Schneider DJ. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction. Am J Cardiol 2000; 85: 491-3, A10.
54. Racanelli AL, Gibbs SK, Zondlo SC, Seiffert DA, Friedman SM, Feuerstein GZ. Differential effect of the GPIIb/IIIa antagonist orbofiban on human platelet aggregate formation in vitro. Thrombosis Research 2003; 110: 99-105.
55. Peter K, Schwarz M, Ylanne J, Kohler B, Moser M, Nordt T, et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood 1998; 92: 3240-9.
56. Peter K, Schwarz M, Nordt T, Bode C. Intrinsic Activating Properties of GP IIb/IIIa Blockers. Thrombosis Research 2001; 103: S21-S7.
57. Ault KA, Cannon CP, Mitchell J, McCahan J, Tracy RP, Novotny WF, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. J Am Coll Cardiol 1999; 33: 634-9.
58. Frelinger AL, Furman MI, Krueger LA, Barnard MR, Michelson AD. Dissociation of Glycoprotein IIb/IIIa Antagonists From Platelets Does Not Result in Fibrinogen Binding or Platelet Aggregation. Circulation 2001; 104: 1374-9.
59. Seiffert D, Thomas B, Bradley J, Munzer D, Tchinnes M, Kornhauser D, et al. Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist. Platelets 2003; 14: 179-87.
60. Andre P, Prasad K, Denis C, He M, Papalia J, Hynes R, et al. CD40L stabilizes arterial thrombi by a beta3 integrin - dependent mechanism. Nat Med 2002; 8: 247-52.
61. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory Effects of Glycoprotein IIb/IIIa Antagonists and Aspirin on the Release of Soluble CD40 Ligand During Platelet Stimulation. Circulation 2003; 107: 1123-8.
62. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, et al. the CAPTURE Study Investigators. Soluble CD40 Ligand in Acute Coronary Syndromes. N Engl J Med 2003; 348: 1104-11.
63. Zondlo SC, Wang X, Feuerstein GZ. Effects of orally active glycoprotein IIb/IIIa antagonists on platelet CD40 ligand (CD154) expression and platelet-heteroaggregate formation. Thrombosis Research 2002; 106: 35-40.
64. Buckley C, Pilling D, Henriquez N, Parsonage G, Threlfall K, Scheel-Toellner D, et al. RGD peptides induce apoptosis by direct caspase-3 activation. Nature 1999; 397: 534-9.
65. Adderley S, Fitzgerald D. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation. J Biol Chem 2000; 275: 5760-6.
66. Erhardt J, Ohlstein E, Toomey J, Gabriel M, Willette R, Yue T, et al. Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban. Thromb Res 2001; 103: 143-8.
67. Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002; 99: 2054-9.
68. Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002; 100: 2071-6.
69. Billheimer JT, Dicker IB, Wynn R, Bradley JD, Cromley DA, Godonis HE, et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood 2002; 99: 3540-6.
70. Brassard J, Curtis B, Cooper R, Ferguson J, Komocsar W, Ehardt M, et al. Acute Thrombocytopenia in Patients Treated with the Oral Glycoprotein IIb/IIIa Inhibitors Xemilofiban and Orbofiban: Evidence for an Immune Etiology. Thromb Haemo 2002; 88: 892-7.
71. Mousa SA, Bozarth JM, Naik UP, Slee A. Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban. Brit J Pharmacol 2001; 133: 331-6.
72. O'Connor FF, Shields DC, Fitzgerald A, Cannon CP, Braunwald E, Fitzgerald DJ. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 2001; 98: 3256-60.
73. Shields D, Fitzgerald A, O'Neill P, Muckian C, Kenny D, Moran B, et al. The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists. Pharmacogenomics J 2002; 2: 182-90.
74. Rozalski M, Watala C. Antagonists of platelet fibrinogen receptor are less effective in carriers of Pl(A2) polymorphism of beta(3) integrin. Eur J Pharmacol 2002; 454: 1-8.
75. Baba K, Aga Y, Nakanishi T, Motoyama T, Ueno H. UR-3216: a manageable oral GPIIb/IIIa antagonist. Cardiovasc Drug Rev 2001; 19: 25-40.
76. Avci FY, Karst NA. and Linhardt RJ. Synthetic oligosaccharides as heparin-mimetics displaying anticoagulant properties. Curr Pharm Design 2003; 9(28): 2323-35.
77. Gould WR. and Leadley RJ. Recent advances in the discovery and development of direct coagulation factor Xa inhibitors. Curr Pharm Design 2003; 9(28): 2337-47.
78. Mousa SA. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond. Curr Pharm Design 2003; 9(28): 2317-22.